Citadel Advisors LLC reduced its position in shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) by 41.8% in the second quarter, according to its most recent filing with the SEC. The fund owned 474,748 shares of the company’s stock after selling 341,619 shares during the quarter. Citadel Advisors LLC owned about 0.83% of DBV TECHNOLOGIE/S worth $9,158,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Jennison Associates LLC grew its stake in DBV TECHNOLOGIE/S by 17.0% in the second quarter. Jennison Associates LLC now owns 1,707,732 shares of the company’s stock valued at $32,942,000 after purchasing an additional 247,523 shares during the last quarter. Janus Henderson Group PLC grew its stake in DBV TECHNOLOGIE/S by 6.0% in the second quarter. Janus Henderson Group PLC now owns 3,022,888 shares of the company’s stock valued at $58,312,000 after purchasing an additional 169,765 shares during the last quarter. Millennium Management LLC grew its stake in DBV TECHNOLOGIE/S by 842.6% in the first quarter. Millennium Management LLC now owns 133,256 shares of the company’s stock valued at $3,074,000 after purchasing an additional 119,119 shares during the last quarter. Bailard Inc. purchased a new position in DBV TECHNOLOGIE/S in the first quarter valued at about $1,084,000. Finally, First Midwest Bank Trust Division grew its stake in DBV TECHNOLOGIE/S by 36.7% in the second quarter. First Midwest Bank Trust Division now owns 136,986 shares of the company’s stock valued at $2,642,000 after purchasing an additional 36,798 shares during the last quarter. Hedge funds and other institutional investors own 44.67% of the company’s stock.
Shares of DBV TECHNOLOGIE/S stock traded up $0.28 on Friday, reaching $23.81. The company’s stock had a trading volume of 149,904 shares, compared to its average volume of 161,951. DBV TECHNOLOGIE/S has a 52-week low of $16.65 and a 52-week high of $50.57. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.37 and a current ratio of 4.37.
A number of equities research analysts have recently weighed in on the company. Stifel Nicolaus assumed coverage on DBV TECHNOLOGIE/S in a research note on Thursday. They set a “buy” rating and a $35.00 price target on the stock. Zacks Investment Research upgraded DBV TECHNOLOGIE/S from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research note on Tuesday, July 31st. BidaskClub raised DBV TECHNOLOGIE/S from a “hold” rating to a “buy” rating in a report on Tuesday, August 28th. Morgan Stanley lifted their target price on DBV TECHNOLOGIE/S from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, July 13th. Finally, ValuEngine raised DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $37.63.
DBV TECHNOLOGIE/S Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Featured Article: Book Value Of Equity Per Share – BVPS Explained
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.